Tapentadol prolonged release (Palexia® SR)
All Wales Medicines Strategy Group (AWMSG)
Record ID 32012000349
Authors' recommendations: Tapentadol prolonged release (Palexia® SR) is recommended as an option for restricted use within NHS Wales, only in the following subpopulation within its licensed indication: Patients with severe chronic pain, in whom morphine sulphate modified release has failed to provide adequate pain control or is not tolerated. Tapentadol prolonged release (Palexia® SR) is not recommended for the management of severe chronic pain in adults, which can be adequately managed only with opioid analgesics, outside of the subpopulation described above. AWMSG is of the opinion that tapentadol prolonged release (Palexia® SR) should be initially prescribed by a specialist*. Prescribing may be continued in primary care with appropriate communication and specialist input. *Specialist implies specialist team or GP with special interest (GPwSI) with appropriate accreditation from the specialist faculty.
Project Status: Completed
Year Published: 2011
URL for published report: http://www.wales.nhs.uk/sites3/docmetadata.cfm?orgid=371&id=184835&pid=24773
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Wales, United Kingdom
- Chronic Disease
Organisation Name: All Wales Medicines Strategy Group
Contact Address: All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name: AWTTC@wales.nhs.uk
Contact Email: AWTTC@wales.nhs.uk
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.